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Summary
 
BACKGROUND
 
 
 
Conventional hormone replacement
therapy (HRT) containing conjugated equine oestrogen
(CEE) and medroxyprogesterone acetate (MPA) incre-
ases triglyceride, C-reactive protein (CRP) and coagul-
ation Factor VII concentrations, potentially explaining
their increased coronary heart disease (CHD) and stroke
risk.
 
OBJECTIVE
 
 
 
To assess the metabolic effects of a
continuous combined HRT containing 1 mg oestradiol
and 0·5 mg norethisterone or matching placebo.
 
DESIGN
 
 
 
Double-blind, randomized placebo-controlled
trial.
 
PATIENTS
 
 
 
Fifty women with type 2 diabetes.
 
MEASUREMENTS
 
 
 
Classical and novel risk factors for
vascular disease.
 
RESULTS
 
 
 
Triglyceride concentration was not altered
(
 
P
 
 = 0·31, change in active arm relative to placebo) and
low-density lipoprotein (LDL) cholesterol concentra-
tion declined 13% (
 
P
 
 = 0·018). IL-6 concentration (mean
difference −
 
1·42 pg/ml, 95% CI: −
 
2·55 to –0·29 IU/dl,
 
P
 
 = 0·015), Factor VII (−
 
32 IU/dl, −
 
43 to −
 
21 IU/l, 
 
P
 
 < 0·001)
and tissue plasminogen activator antigen (by 13%,
 
P
 
 = 0·005) concentrations fell, but CRP was not signif-
icantly altered (
 
P
 
 = 0·62). Fasting glucose (
 
P
 
 = 0·026)
also declined significantly, but there are no significant
effects on HBA1c, Factor IX or APC resistance.
 
CONCLUSIONS
 
 
 
HRT containing 1 mg oestradiol and
0·5 mg norethisterone may avoid the adverse metabolic
effects potentially implicated in the elevated CHD and
stroke risk induced by conventional higher dose HRT.
This type of preparation may therefore be more suitable
than conventional HRT for women at elevated CHD risk
such as those with type 2 diabetes. Large randomized
controlled trials of such low dose preparations, powered
for cardiovascular end points, are now needed.
 
Until the publication of the Heart and Oestrogen/Progestogen
Replacement Study (HERS; Hulley 
 
et al
 
., 1998), and more
recently of the Women’s Health Initiative (WHI) study (Rossouw
 
et al
 
., 2002), many women and their physicians were convinced
of the cardio-protective effects of hormone replacement therapy
(HRT). In HERS, women with established CHD were randomized
to 0·625 mg/day conjugated equine oestrogen (CEE) plus
2·5 mg/day medroxy-progesterone acetate (MPA) or matching
placebo. The HRT group experienced an elevation in coronary
heart disease (CHD) risk in the first year of use and no overall
difference in events over 4 years (Hulley 
 
et al
 
., 1998). The WHI
used the same preparation in a primary prevention setting and
also reported an increased risk of CHD and of stroke in the active
arm compared to placebo (Rossouw 
 
et al
 
., 2002), and more
recently a potential deleterious effect on cognitive function (Rapp
 
et al
 
., 2003). Therefore, despite a beneficial effect of this prep-
aration on low-density lipoprotein (LDL) and HDL cholesterol
concentrations, other effects may be unfavourable; the search for
these is receiving intense scrutiny. Most current attention has
focussed on possible triglyceride-raising, pro-coagulant and
pro-inflammatory effects of CEE and 2 mg oestradiol containing
HRTs (Kroon 
 
et al
 
., 1994; Petitti, 1998; van Baal 
 
et al
 
., 1999b;
Cushman 
 
et al
 
., 1999; Ridker 
 
et al
 
., 1999; Lowe 
 
et al
 
., 2001b) but
data on preparations containing low dose oestradiol combined to
norethisterone, particularly from randomised placebo-controlled
trials, are sparse.
Women with type 2 diabetes have a markedly elevated baseline
risk for CHD. A recent report from a prospective observational
study (Lokkegaard 
 
et al
 
., 2003) suggested that HRT use leads to
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a significantly increased risk of death from all causes and
ischaemic heart disease among women with diabetes. Current
users of HRT with diabetes had a near 10-fold increased risk of
myocardial infarction [9·2, 95% confidence interval (CI), 2·0–
41·4] compared with never users with diabetes. By contrast,
Ferrara 
 
et al
 
. (2003) noted that among diabetic women who did
not have a recent myocardial infarction, current HRT use was
associated with a significant 16% lower risk of acute myocardial
infarction. Thus HRT effects on CHD risk in diabetes are con-
troversial and randomized trials are required.
HRT preparations are not homogeneous with respect to
metabolic effects: metabolic actions are profoundly altered accord-
ing to route of delivery, dose and chemical nature of the combined
oestrogenic and progestogenic preparations (Knopp & Zhu, 1997).
Data from trials with differing designs suggest that lower doses
of oestradiol (1 mg) or transdermal preparations may have fewer
deleterious and (perhaps) even beneficial effects on inflammatory
and haemostatic pathways (van Baal 
 
et al
 
., 1999a; Sattar 
 
et al
 
.,
1999; Lowe 
 
et al
 
. 
 
et al.
 
, 2001b; Perera 
 
et al
 
., 2001; Vehkavaara
 
et al
 
., 2001). In addition, there is an increasing awareness that
androgenic progestogens such as norethisterone may offer several
advantages over MPA, particularly with respect to coagulation and
inflammatory parameters (Sattar 
 
et al
 
., 1999; Perera 
 
et al
 
., 2001).
The aim of the present randomized double-blind placebo-
controlled study therefore was to examine the metabolic effects
of a novel continuous combined preparation containing 1 mg
oestradiol and 0·5 mg norethisterone in women with type 2
diabetes. We comprehensively assessed key pathways, including
lipids and glycaemic parameters, and haemostatic and inflamma-
tory pathways, known to be influenced by hormonal regulation
and relevant to CHD risk. The hypothesis was that this low-dose
oestradiol preparation combined with norethisterone would
continue to reduce LDL cholesterol, limit any triglyceride rise and
would have fewer potentially adverse effects on key coagulation
and inflammatory parameters than observed with conventional
CEE/MPA-based preparations.
 
Methods
 
Subjects
 
From December 1998 to September 2000, 50 women with type
2 diabetes aged under 70 years of age were recruited from general
diabetic clinics in Glasgow Hospitals. Women randomized were
clinically and biochemically postmenopausal, i.e. at least 1 year
since last menses and a FSH concentration of greater than 20 IU/
l. Menopause could be either natural or surgically induced. A
normal pelvic examination and mammogram within the year
prior to inclusion in the trial was also required.
Exclusion criteria comprised: poor glycaemic control; severe
hypertriglyceridaemia (> 10 mmol/ l); moderate to severe hyper-
tension (systolic > 160 mmHg, diastolic > 110 mmHg); renal
impairement (serum creatinine greater than twice the upper
limit of normal range); liver disease (serum transaminases and
bilirubin greater than twice the upper limit of normal range); or
established cardiovascular, cerebrovascular, or peripheral vascular
disease. Subjects with either a personal history of – or first-degree
relative with – breast cancer were excluded.
Women eligible at screening were randomized to prescription
of either active medication (1 mg oestradiol plus 0·5 mg
norethisterone) or identical placebo daily for 6 months. Random-
ization was effected in blocks of four using computer-generated
numbers. Compliance was assessed by returned medication packs
at the final visit and by oestradiol and gonadotrophin concentration
measures at the final visit. A requirement of oestradiol to rise by
more than10 pmol/ l and FSH to decline by more than 5 U/ l was
predefined.
The participating hospitals’ local research ethical committees
granted approval. All subjects gave written informed consent to
a single investigator (JM). As far as possible, existing medica-
tions for glycaemic control, blood pressure or lipid lowering
(detailed in Table 1) were not altered throughout the course of
the study.
We determined that our sample size had 80% power to detect
a 5% reduction in LDL cholesterol and 90% power to detect a
5% reduction in factor VII with 
 
α
 
 = 0·05.
 
Study visits
 
Women attended the Diabetes Centre, Glasgow Royal Infir-
mary, Glasgow at baseline and 6 months, having fasted for
10 h and avoided heavy exercise, alcohol and caffeine in the
Table 1 Baseline characteristics of study groups
 
Group
Active, n = 19 Placebo, n = 22
Age (years) 60·7 (5·5) 61·3 (4·8)
BMI (kg/m2) 30·5 (6·5) 29·8 (5·61)
Waist circumference (cm) 93·9 (11·3) 93·7 (13·6)
Years postmenopausal 14·6 (8·5) 14·2 (6·3)
Smokers (yes/no) 6/19 5/22
Systolic blood pressure (mmHg) 152 (17) 151 (21)
Diastolic blood pressure (mmHg) 87 (8) 83 (9)
Medications
Diet alone (n) 5 3
Oral hypoglycaemics (n) 10 11
Insulin (n) 4 9
Anti-hypertensives (n) 10 10
Lipid-lowering agents (n) 5 5
Mean (SD) reported.
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preceding 24 h. Subjects rested prone for 15 min prior to
blood pressure recordings being taken in triplicate (mean
recorded). The women also had anthropometric measurements to
include height (cm), weight (kg) and waist and hip circumfer-
ences (cm). From these, body mass index (BMI) was calculated
as weight/(height)
 
2
 
 in kg/m
 
2
 
, as well as waist to hip ratio
(WHR).
 
Laboratory methods
 
The reproductive hormones: oestradiol, LH, FSH, testosterone
and SHBG were measured using semiautomated ‘Immulite’
technology (DPC, Los Angeles, CA, USA). Plasma total choles-
terol, triglyceride, LDL cholesterol and HDL cholesterol were
determined by a modification of the standard Lipid Research
Clinics Protocol. The intra-assay and interassay coefficients of
variation (CVs) for lipid measures were both less than 3%.
Fibrinogen, factor VII and factor IX, activated protein C (APC)
ratio and tissue plasminogen activator (t-PA) antigen were
measured in citrated plasma (0·11 
 
m
 
 trisodium citrate; 9 : 1, v : v)
as previously described (Woodward 
 
et al
 
., 1997; Lowe 
 
et al
 
.,
1998, 2001a). The APC ratio measurement was an APTT-based
test rather than a Factor V prediluted test. The intra-assay CVs
for these haemostatic mediators were all less than 5%. C-peptide
was measured using the DPC Immulite 2000 analyser with a CV
of < 7%. Plasma glucose was measured using the glucose oxidase
method (Glucose Reagent Kit – Olympus AU5200, Olympus
Optical Co Ltd, Tokyo, Japan).
CRP concentration was measured using an in-house sensitive
double antibody sandwich enzyme-linked immunosorbent assay
(ELISA) as described previously (Sattar 
 
et al
 
., 1999). The assay
was linear up to 5 mg/ l and logarithmic thereafter, and had a
lower detection limit of 0·10 mg/ l. The inter- and intra-assay
coefficients of variation were less than 10% across the range of
measured results. Sensitive IL-6 was measured by double
antibody sandwich ELISA (R & D Systems, Minneapolis, MN,
USA) with an intra-assay CV of 8%.
 
Statistical analysis
 
Mean differences in changes from baseline between the two treat-
ment groups were compared using the unpaired 
 
t
 
-test: the 95%
CI for change in active group data relative to change in control
group data are presented. Adjustment for baseline concentrations
was made by linear regression. Baseline data are presented as
mean and SD or median and interquartile range (IQR) for
parameters exhibiting skewed distribution.
 
Results
 
Fifty-eight women were screened as potential recruits into the
study. Of these, 50 were randomized (Fig. 1). The eight women
not entered had unacceptably high HbA1c (
 
n
 
 = 3), abnormal liver
function tests (
 
n
 
 = 2), abnormal mammogram (
 
n
 
 = 2) or abnormal
pelvic examination (
 
n
 
 = 1). Five women did not complete the study
due to either relocating or personal reasons. Thus, 45 women
completed the study: of the 22 in the active group, 19 demon-
strated adherence to study medications by predetermined criteria.
Data from women falling outside these criteria were omitted
from subsequent analyses. There were no serious adverse
events. Breast tenderness and breakthrough bleeding were
reported by three women on active treatment and by none on
placebo.
Table 1 demonstrates the baseline characteristics of women
completing the study. The two groups allocated to treatment were
similar in age, BMI, blood pressure and years since menopause.
All categories of diabetes therapy were represented and similar
percentages were taking antihypertensive or lipid-lowering agents.
The treatment groups also showed similar baseline hormonal and
lipid concentrations (Tables 2 and 3).
A significant reduction in gonadotrophin concentrations and
an elevation in oestradiol (all 
 
P
 
 < 0·001) and SHBG levels
(
 
P
 
 = 0·042) was observed in those women randomized to active
therapy as a group (Table 2). Total testosterone was not altered
significantly but free androgen index fell significantly (
 
P
 
 < 0·001,
data not shown).
Table 3 demonstrates lipid and glycaemic changes in the
groups. Both total (10%) and LDL cholesterol (13%) concentra-
tions were reduced significantly with active treatment (
 
P
 
 < 0·05)
but HDL cholesterol and triglyceride were not altered. Similarly,
fasting C-peptide was reduced by 19% (
 
P
 
 < 0·01 
 
vs.
 
 change in
placebo). Fasting glucose was also reduced (
 
P
 
 < 0·05) in the
active arm as was HbA1c but the latter change did not reach
significance (
 
P
 
 > 0·10).
Haemostatic and inflammatory variables are presented in
Table 4. Significant reductions in Factor VII levels (
 
P
 
 < 0·001),
and t-PA antigen and IL-6 concentrations (
 
P
 
 < 0·02) were
observed without significant alteration in factor IX, APC resist-
ance (APC ratio), fibrinogen or CRP concentrations.
Fig. 1 Trial outcome flow chart.
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Significance values were also checked with adjustment for base-
line concentrations of all parameters measured. The results were in
keeping with unadjusted values: specifically, reductions in cho-
lesterol (adjusted 
 
P
 
 = 0·032), Factor VII (adjusted 
 
P
 
 < 0·001), tPA-
antigen (adjusted 
 
P
 
 = 0·01) and IL-6 (adjusted 
 
P
 
 = 0·045) were
similar and CRP remained similarly unchanged (adjusted 
 
P
 
 = 0·96).
Finally, we determined the number of patients randomized to
HRT or placebo that achieved 10% decline in LDL cholesterol
Table 3 Lipids and insulin/glycaemia changes in active and placebo groups
 
Active Placebo
Difference for ∆ active relative
to ∆ placebo (95% CI) PBaseline
Mean
change Baseline
Mean
change
Lipids
Cholesterol (mmol/ l) 6·02 (1·07) −0·62 5·68 (0·97) −0·13 −0·49 (−0·05–(−0·90)) 0·020
LDL-C (mmol/ l) 4·14 (0·93) −0·55 3·80 (1·00) −0·10 −0·44 (−0·79–(−0·08)) 0·018
HDL-C (mmol/ l) 1·30 (0·32) −0·07 1·36 (0·29) −0·06 0·01 (−0·10–0·10) 0·830
Chol:HDL-C ratio 4·88 (1·58) −0·28 4·46 (1·53) 0·20 −0·48 (−0·99–0·00) 0·050
Triglyceride (mmol/ l) 1·75 (1·15–2·35) −0·034 1·68 (1·25–2·21) 0·16 −0·19 (−0·58–0·19) 0·310
Glycaemia
C-peptide (nmol/ l) 0·97 (0·65–1·29) −0·18 0·79 (0·49–1·51) 0·09 −0·27 (−0·44–(−0·09)) 0·003
Glucose (mmol/ l) 12·4 (4·2) −1·74 11·3 (3·2) 0·42 −2·16 (−4·06–(−0·28)) 0·026
HBA1c (%) 10·2 (1·8) −0·37 10·2 (1·3) 0·22 −0·59 (−1·45–0·27) 0·170
Baseline data are given as mean (SD) or median (interquartile range).
Table 4 Haemostatic and inflammatory changes in active and placebo groups
 
Active Placebo 
Difference for ∆ active relative
to ∆ placebo (95% CI) PBaseline
Mean
change Baseline
Mean
change
Haemostatic factors
Factor VII (IU/dl)  160 (36) −26·7  152 (31) 5·50 −32 (−43–(−21)) < 0·001
Factor IX (IU/dl)  163 (42) 7·00  155 (40) 3·60 3·7 (−9·9–16·3) 0·490
APC ratio 2·74 (0·6) 0·25 2·74 (0·5) 0·23 0·0 (−0·25–0·25) 0·990
tPA-antigen (ng/ml) 14·9 (5·6) −2·01 12·7 (3·8) 0·97 −2·98 (−5·00–(−0·95)) 0·005
Fibrinogen (g/ l) 3·91 (0·68) 0·02 3·89 (0·92) −0·12 0·14 (−0·19–0·47) 0·390
Inflammatory factors
CRP (mg/l) 5·05 (4·46–8·53) 1·45 3·37 (1·76–8·10) 0·72 0·73 (−2·27–3·72) 0·620
IL-6 (pg/ml) 3·46 (2·48–4·89) −0·32 3·55 (2·11–4·47) 1·10
−1·42 (−2·55–(−0·29)) 0·015
Baseline data are given as mean (SD) or median (interquartile range).
Table 2 Sex hormone changes in active and placebo groups
 
Active Placebo
Difference for ∆ active relative
to ∆ placebo (95% CI) PBaseline
Mean
change Baseline
Mean
change
LH (IU/l)  35 (26–39) −23·7 37 (24−44) −0·4 −23 (−32–(−15)) < 0·001
FSH (IU/l)  53 (49–83) −41·8 60 (48–81) −2·5 −39 (−50–(−28)) < 0·001
Oestradiol (pmol/ l) 63·3 (15·9) 165 65·4 (14·6) 2·0 163 (111−215) < 0·001
Testosterone (nmol/ l) 1·23 (0·63) −0·12 1·19 (0·33) 0·0 −0·12 (−0·42−0·17) 0·410
SHBG (nmol/ l)  33 (21–52) 15·7 37 (27−49) 1·4 14·3 (0·52−28·1) 0·042
Baseline data are given as mean (SD) or median (interquartile range).
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and Factor VII concentration using an intention to treat analysis.
A 10% decline is either parameter in clinically relevant. Ten of
the 25 in the HRT group had > 10% decline in LDL cholesterol
compared to only four in the placebo group (P = 0·059, Chi-
square test). For Factor VII, 16 of the 25 in the HRT group had
> 10% decline in Factor VII, whereas only one of the 25 in the
placebo group did so (P < 0·0001).
Discussion
Our study is one of the very few randomized double-blind
placebo-controlled trials of HRT in diabetic women, albeit in an
older group than those who would normally receive HRT. More
importantly, it is the largest study to date to examine metabolic
actions of a novel continuous combined preparation containing
1 mg oral oestradiol and 0·5 mg norethisterone in a high CHD-
risk population. The key results were lowered plasma LDL
cholesterol, Factor VII, t-PA antigen and IL-6 concentrations, and
statistically similar triglyceride, Factor IX, APC resistance and
CRP levels. This pattern of effects differs markedly from the
profile produced by normal-dose HRT containing CEE and
MPA used in HERS and WHI which increase triglyceride, Factor
VII and promote a doubling in CRP concentrations (Hulley et al.,
1998; Petitti, 1998). As a result, an HRT containing low-dose
oestradiol and norethisterone may be more suitable for women
who have an elevated risk of CHD (e.g. those with type 2 diabetes),
who require HRT for menopausal symptom relief or bone pro-
tection. Formal clinical trials are required to test this suggestion.
The potentially better portfolio of metabolic effects of the HRT
in this study may result either from the use of a low oestradiol
dose or from the use of a more androgenic progestogen, nore-
thisterone. More likely is that the balance of effects deriving from
this HRT lean more towards androgenic rather than oestrogenic
actions. This is an important point as conventional wisdom has
dictated the use of nonandrogenic progestogens to minimize any
HDL cholesterol reducing effect (Petitti, 1998). Clearly, this
course of action needs re-evaluation as HDL cholesterol was
unchanged in the present study.
With respect to the inflammation cascade, HRTs containing
2 mg oestradiol or CEE elevate CRP concentrations almost
twofold (Ridker et al., 1999; Lowe et al., 2001b). In the obser-
vational arm of the (large) WHI, current HRT use was associated
with higher CRP but, interestingly, similar IL-6 levels in those
women not taking HRT (Pradhan et al., 2002). Moreover,
transdermal delivery of oestradiol appears not to be associated
with elevation of CRP (Sattar et al., 1999; Lowe et al., 2001b;
Vehkavaara et al., 2001) which therefore may represent a ‘first
pass’ effect on hepatic CRP synthesis (Lowe et al., 2001b).
Because elevated CRP levels in men and women are independ-
ently linked to risk for CHD and stroke (Ridker, 2001), the HRT-
induced CRP rise has been put forward as a potential pathway
explaining the results of HERS and WHI (Kroon et al., 1994;
Ridker et al., 1999). It should be acknowledged, however, that
even though vascular literature suggests several mechanisms
whereby CRP may be directly atherogenic (Ridker, 2001), it is
not yet known whether the HRT-induced CRP rise leads directly
or indirectly to a biologically adverse outcome.
Our data demonstrate a lack of significant rise in CRP in those
assigned active therapy compared to the placebo group (P = 0·62
crude, P = 0·96 adjusted difference). Although power may be an
issue here, studies in similar size to the present one, but employing
CEE- or 2 mg oestradiol-based preparations, have demonstrated
significant, near twofold elevations in CRP (van Baal et al., 1999b;
Manning et al., 2002). A lack of CRP rise in the present study
concurs with results from two other studies in nondiabetic women
that used lower oestradiol doses (1 mg; van Baal et al., 1999a;
Stork et al., 2002). Moreover, HRT combining oral norethisterone
with transdermal oestradiol may lower CRP (Sattar et al., 1999);
thus any tendency to an oestradiol-induced CRP elevation in
the present study may have been attenuated by the oral norethis-
terone. The reduction in IL-6 concentration is of interest as
androgens exhibit anti-inflammatory effects in several tissues
(Gornstein et al., 1990). Because of the variability of circulating
inflammatory markers and the wide confidence interval in the
result reported in this and studies of similar size (van Baal et al.,
1999a; Zanger et al., 2000), larger studies using low-dose HRT
preparations are now urgently required to confirm our findings.
In this respect, a potentially lower CHD risk with lower doses of
HRT has recently been suggested by Ferrera et al. (2003) in their
analysis of data from the Northern California Kaiser Permanente
Diabetes Registry.
That triglyceride did not rise in this study is also relevant to
CHD risk. Oral oestrogens, particularly CEE-based preparations,
significantly increase circulating triglyceride concentrations by
increasing hepatic synthesis of triglyceride-rich particles (Knopp
et al., 1997). Increases in triglyceride concentration may enhance
plaque instability by affecting platelet and endothelial function,
as well as altering coagulation and vascular inflammation
(Sattar et al., 1998; Dichtl et al., 1999). Triglyceride concentra-
tion is independently linked to CHD risk, particularly in women
(Hokanson & Austin, 1996). Indeed, the HERS investigators
speculated that the 10% rise in triglyceride concentration in their
study may have contributed to the early increase in CHD events
despite the positive changes in other lipid parameters (Hulley
et al., 1998). In general, increase in triglyceride concentration is
less pronounced with oral oestradiol-containing HRTs compared
to CEE-based HRTs and absent with transdermal delivery (Knopp
et al., 1997). Moreover, androgens decrease triglyceride concen-
tration (Knopp et al., 1997; Perera et al., 2001), thereby opposing
any tendency for an oestradiol-mediated increase.
Consistent with the reduction in Factor VII coagulation activity
(by 17%) with active treatment in this study, similar reductions
Metabolic effects of low-dose HRT in diabetes 687
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have been reported with HRTs combining transdermal oestradiol
with either oral MPA (10 mg; Kroon et al., 1997) or oral 1 mg
norethisterone (Vehkavaara et al., 2001). By contrast, oral 2 mg
oestradiol or 0·625 mg CEE alone increase Factor VII activity,
whereas transdermal oestradiol has a negligible effect (Kroon
et al., 1994; Lowe et al., 2001b; Vehkavaara et al., 2001). These
data strongly suggest that oral progestogens reduce Factor VII
coagulation activity. The reduction in Factor VII herein therefore
indicates an overall hormonal balance favouring a dominant
norethisterone action. Although elevated Factor VII coagulation
activity has been associated with an increased risk of coronary
thrombosis in one study of men (Meade et al., 1980), similar data
in women are lacking. The relevance of HRT-mediated changes
in Factor VII levels therefore requires clarification.
A further potential benefit noted in our study was a reduction
in fasting glucose concentration. Whether this reflects an
improvement in insulin action must be viewed with a degree of
caution as we did not directly measure insulin action using clamp
techniques, and many women were taking insulin therapy. Future
studies should measures insulin action directly. Nevertheless,
although HbA1c was not significantly altered, an improvement in
insulin sensitivity or reduced hepatic glucose production accords
with findings of two previous randomized placebo-controlled
trials in women with diabetes with unopposed oral 2 mg 17β-
oestradiol alone (Anderson et al., 1997; Brussard et al., 1997).
The recent report of a significant reduction in the incidence of
diabetes (by 35%) in women with coronary disease assigned
to active treatment in HERS study as compared to those given
placebo (Kanaya et al., 2003) suggests that conventional HRT
may lessen risk of diabetes. Whether low-dose HRT containing
oestradiol and norethisterone has the same (or even larger) effect
deserves further study.
The observed reduction in tPA-antigen (which largely measures
circulating t-PA-PA1 complexes) is in keeping with a reduction
in PAI-1, which was not directly measured. PAI-1 has also been
shown to fall in oral HRT studies (Koh et al., 1997; Andersen
et al., 1999; Lowe et al., 2001b). Alternatively, the fall in t-PA
may reflect reduced endothelial disturbance (i.e. t-PA release).
Interestingly, elevated tPA-Ag (but not PAI-1) levels independ-
ently predicted CHD event rate in a recent meta-analysis of pro-
spective studies in general populations (Lowe et al., 2001a).
There are several notable strengths of this study. Firstly, it is
one of the very few randomized double-blind placebo-controlled
trials of HRT in diabetic women, a group at elevated baseline
risk of CHD and at potentially elevated CHD risk with conven-
tional HRT therapy (Lokkegaard et al., 2003). Secondly, the novel
low-dose preparation was very well tolerated and the side-effect
profile was excellent, helping maintain investigator blinding.
Thirdly, we tracked adherence to study medication by measuring
oestradiol and gonadotrophin concentrations. Finally, we assessed a
number of key pathways for CHD risk simultaneously, an approach
that facilitated a more comprehensive assessment of the overall
balance of metabolic, haemostatic and inflammatory effects of
the low-dose HRT used. A limitation of our study is the modest
number of patients recruited. Nevertheless, statistically significant
changes detected in several key parameters indicate sufficient power
to detect meaningful changes in pathways of interest; moreover,
the results have biological plausibility. Our data therefore provide
a strong basis for future studies examining the clinical safety of low
dose HRT containing oestradiol and norethisterone in preference
to conventional HRT containing CEE and MPA, supporting an
emerging consensus that lower doses may be the safer option for
many women (Ferrara et al., 2003; Herrington, 2003).
In conclusion, our study shows that low-dose HRT containing
1 mg oestradiol and 0·5 mg norethisterone generates a vastly
different portfolio of metabolic and haemostatic action compared
to that observed with use of conventional higher dose HRT.
Specifically, triglyceride, Factor IX, APC resistance and CRP
levels were statistically similar, whereas IL-6 and Factor VII
levels were significantly reduced and LDL cholesterol lowering was
retained. On the basis of our data, we suggest that a preparation
containing low-dose oestradiol combined with norethisterone
may be more suitable for women who require HRT for meno-
pausal symptom relief or bone protection but who are at higher
risk of CHD, such as those with type 2 diabetes. However, before
definitive recommendations are made, such novel formulations
should be assessed in a large randomized controlled trial powered
for cardiovascular endpoints.
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